459 related articles for article (PubMed ID: 35840984)
21. Rociletinib, a third generation EGFR tyrosine kinase inhibitor: current data and future directions.
Chuang JC; Salahudeen AA; Wakelee HA
Expert Opin Pharmacother; 2016; 17(7):989-93. PubMed ID: 26950414
[TBL] [Abstract][Full Text] [Related]
22. Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance.
Tartarone A; Lerose R
Ther Adv Respir Dis; 2015 Oct; 9(5):242-50. PubMed ID: 26016841
[TBL] [Abstract][Full Text] [Related]
23. Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Non-small-cell Lung Cancer.
Kawamura T; Kenmotsu H; Omori S; Nakashima K; Wakuda K; Ono A; Naito T; Murakami H; Omae K; Mori K; Tanigawara Y; Nakajima T; Ohde Y; Endo M; Takahashi T
Clin Lung Cancer; 2018 Mar; 19(2):e247-e252. PubMed ID: 28866043
[TBL] [Abstract][Full Text] [Related]
24. [Clinical research and drug review of epidermal growth factor receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer].
Zhou M; Chen DM; Xia L; Song YY; Shi YK; Yang ZM
Zhonghua Zhong Liu Za Zhi; 2019 Dec; 41(12):949-952. PubMed ID: 31874554
[TBL] [Abstract][Full Text] [Related]
25. Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer.
Soejima K; Yasuda H; Hirano T
Expert Rev Clin Pharmacol; 2017 Jan; 10(1):31-38. PubMed ID: 27885838
[TBL] [Abstract][Full Text] [Related]
26. Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.
Nurwidya F; Takahashi F; Murakami A; Kobayashi I; Kato M; Shukuya T; Tajima K; Shimada N; Takahashi K
Respir Investig; 2014 Mar; 52(2):82-91. PubMed ID: 24636263
[TBL] [Abstract][Full Text] [Related]
27. MicroRNAs as a drug resistance mechanism to targeted therapies in EGFR-mutated NSCLC: Current implications and future directions.
Leonetti A; Assaraf YG; Veltsista PD; El Hassouni B; Tiseo M; Giovannetti E
Drug Resist Updat; 2019 Jan; 42():1-11. PubMed ID: 30544036
[TBL] [Abstract][Full Text] [Related]
28. Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.
Marquez-Medina D; Popat S
Future Oncol; 2015 Sep; 11(18):2525-40. PubMed ID: 26314834
[TBL] [Abstract][Full Text] [Related]
29. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.
Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J
Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341
[TBL] [Abstract][Full Text] [Related]
30. Emerging Approaches to Overcome Acquired Drug Resistance Obstacles to Osimertinib in Non-Small-Cell Lung Cancer.
Shaikh M; Shinde Y; Pawara R; Noolvi M; Surana S; Ahmad I; Patel H
J Med Chem; 2022 Jan; 65(2):1008-1046. PubMed ID: 34323489
[TBL] [Abstract][Full Text] [Related]
31. Overcoming Resistance to EGFR Inhibitors in NSCLC.
Maione P; Sacco PC; Casaluce F; Sgambato A; Santabarbara G; Rossi A; Gridelli C
Rev Recent Clin Trials; 2016; 11(2):99-105. PubMed ID: 27028971
[TBL] [Abstract][Full Text] [Related]
32. Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.
Liao BC; Lin CC; Yang JC
Curr Opin Oncol; 2015 Mar; 27(2):94-101. PubMed ID: 25611025
[TBL] [Abstract][Full Text] [Related]
33. Recent understanding of the molecular mechanisms for the efficacy and resistance of EGF receptor-specific tyrosine kinase inhibitors in non-small cell lung cancer.
Nakata A; Gotoh N
Expert Opin Ther Targets; 2012 Aug; 16(8):771-81. PubMed ID: 22762482
[TBL] [Abstract][Full Text] [Related]
34. Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance.
Patel H; Pawara R; Ansari A; Surana S
Eur J Med Chem; 2017 Dec; 142():32-47. PubMed ID: 28526474
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of Next-Generation EGFR-TKIs in Patients With Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.
Qi YT; Hou Y; Qi LC
Technol Cancer Res Treat; 2020; 19():1533033820940426. PubMed ID: 32723164
[TBL] [Abstract][Full Text] [Related]
36. Clinical management of third-generation EGFR inhibitor-resistant patients with advanced non-small cell lung cancer: Current status and future perspectives.
Zhang YC; Zhou Q; Wu YL
Cancer Lett; 2019 Sep; 459():240-247. PubMed ID: 31201840
[TBL] [Abstract][Full Text] [Related]
37. [Targeted Therapy and Mechanism of Drug Resistance in Non-small Cell Lung Cancer
with Epidermal Growth Factor Receptor Gene Mutation].
Huang J; Wang H
Zhongguo Fei Ai Za Zhi; 2022 Mar; 25(3):183-192. PubMed ID: 35340161
[TBL] [Abstract][Full Text] [Related]
38. Strategies to overcome acquired resistances conferred by mutations in the kinase domain of EGFR.
Lim SM; Jeong Y; Hong S
Future Med Chem; 2016 May; 8(8):853-78. PubMed ID: 27195594
[TBL] [Abstract][Full Text] [Related]
39. Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer.
Ricordel C; Friboulet L; Facchinetti F; Soria JC
Ann Oncol; 2018 Jan; 29(suppl_1):i28-i37. PubMed ID: 29462256
[TBL] [Abstract][Full Text] [Related]
40. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Central Nervous System Metastases from Non-Small Cell Lung Cancer.
Ahluwalia MS; Becker K; Levy BP
Oncologist; 2018 Oct; 23(10):1199-1209. PubMed ID: 29650684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]